Guided Therapeutics (GTHP) versus Its Competitors Head-To-Head Comparison

Guided Therapeutics (OTCMKTS:GTHP) is one of 71 public companies in the “Electromedical equipment” industry, but how does it contrast to its peers? We will compare Guided Therapeutics to similar companies based on the strength of its valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.

Earnings & Valuation

This table compares Guided Therapeutics and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-5.83
Guided Therapeutics Competitors	$1.06 billion	$88.76 million	-8.38

Guided Therapeutics’ peers have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

9.7% of Guided Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of shares of all “Electromedical equipment” companies are owned by institutional investors. 66.8% of Guided Therapeutics shares are owned by company insiders. Comparatively, 13.2% of shares of all “Electromedical equipment” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Guided Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Guided Therapeutics Competitors	266	798	1967	59	2.59

As a group, “Electromedical equipment” companies have a potential upside of 3,107.40%. Given Guided Therapeutics’ peers higher probable upside, analysts plainly believe Guided Therapeutics has less favorable growth aspects than its peers.

Profitability

This table compares Guided Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-341.23%	-95.28%	-31.21%

Volatility & Risk

Guided Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ peers have a beta of 1.02, meaning that their average share price is 2% more volatile than the S&P 500.

Summary

Guided Therapeutics peers beat Guided Therapeutics on 6 of the 10 factors compared.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.